The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

被引：34
|
作者：
Nazha, Aziz [1 ,2 ]
Komrokji, Rami S. [3 ]
Garcia-Manero, Guillermo [4 ]
Barnard, John [5 ]
Roboz, Gail J. [6 ]
Steensma, David P. [7 ]
DeZern, Amy E. [8 ]
Zell, Katrina [5 ]
Zimmerman, Cassie [1 ,2 ]
Al Ali, Najla [3 ]
Jabbour, Elias [4 ]
Greenberg, Molly D. [6 ]
Kantarjian, Hagop M. [4 ]
Maciejewski, Jaroslaw P. [1 ,2 ]
List, Alan F. [3 ]
Sekeres, Mikkael A. [1 ,2 ]
机构：
[1] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[5] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA
[6] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA
[7] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 06期
关键词：
MDS; hypomethylating agent; prognostic models; SCORING SYSTEM; CLASSIFICATION; AZACITIDINE; PROPOSAL;
D O I：
10.3324/haematol.2015.140962
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E224 / E227
页数：4
相关论文
共 43 条
  • [21] Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
    Nazha, Aziz
    Sekeres, Mikkael A.
    Komrokji, Rami
    Steensma, David P.
    Kantarjian, Hagop
    Roboz, Gail
    Fenaux, Pierre
    Prebet, Thomas
    Azarnia, Nozar
    Zbyszewski, Patrick S.
    Fruchtman, Steven M.
    Santini, Valeria
    Silverman, Lewis R.
    Platzbecker, Uwe
    Garcia-Manero, Guillermo
    BLOOD CANCER JOURNAL, 2017, 7
  • [22] Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
    Geng, Suxia
    Xu, Ruohao
    Huang, Xin
    Li, Minming
    Deng, Chengxin
    Lai, Peilong
    Wang, Yulian
    Wu, Ping
    Chen, Xiaomei
    Weng, Jianyu
    Du, Xin
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes
    Yoo Jin Lee
    Sung Woo Park
    In Hee Lee
    Jae Sook Ahn
    Hyeoung Joon Kim
    Joo Seop Chung
    Ho Jin Shin
    Won Sik Lee
    Sang Min Lee
    Young Don Joo
    Hawk Kim
    Ho Sup Lee
    Yang Soo Kim
    Yoon Young Cho
    Joon Ho Moon
    Sang Kyun Sohn
    Annals of Hematology, 2016, 95 : 1795 - 1804
  • [24] Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy
    Cogle, Christopher R.
    Ortendahl, Jesse D.
    Bentley, Tanya G. K.
    Anene, Ayanna M.
    Megaffin, Scott
    McKearn, Thomas J.
    Petrone, Michael E.
    Mukherjee, Sudipto
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 275 - 284
  • [25] Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
    Prebet, Thomas
    Toma, Andrea
    Cluzeau, Thomas
    Sekeres, Mikkael A.
    Vey, Norbert
    Park, Sophie
    Al Ali, Najla
    Sugrue, Marie M.
    Komrokji, Rami
    Fenaux, Pierre
    Gore, Steven D.
    ONCOTARGET, 2017, 8 (23) : 37866 - 37874
  • [26] A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure
    Chien, Kelly S.
    Rodriguez-Sevilla, Juan Jose
    Alvarado, Yesid
    Montalban-Bravo, Guillermo
    Hammond, Danielle E.
    Swaminathan, Mahesh
    Bazinet, Alexandre
    Kimberley, Jacqueline
    Bodden, Kristy
    Schneider, Heather
    Dong, Xiao Qin
    Pierce, Sherry A.
    Huang, Xuelin
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    LEUKEMIA RESEARCH, 2024, 147
  • [27] Efficacy and prognostic assessment of chemotherapy-bridged transplantation in pediatric patients with advanced myelodysplastic syndromes
    Wang, Xingchen
    Liu, Chenmeng
    Chen, Yunlong
    Wan, Yang
    An, Wenbin
    Li, Xiaolan
    Liu, Lipeng
    Liu, Fang
    Zhang, Li
    Zou, Yao
    Chen, Xiaojuan
    Chen, Yumei
    Guo, Ye
    Zhu, Xiaofan
    Yang, Wenyu
    BONE MARROW TRANSPLANTATION, 2024, : 403 - 405
  • [28] Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes
    Zeidan, Amer M.
    Joshi, Namita
    Kale, Hrishikesh
    Wang, Wei-Jhih
    Corman, Shelby
    Salimi, Tehseen
    Epstein, Robert S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (09) : 670 - 679
  • [29] A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients With Myelodysplastic Syndromes After Hypomethylating Agent (HMA) Failure
    Chien, Kelly
    Rodriguez-Sevilla, Juan Jose
    Alvarado, Yesid
    Montalban-Bravo, Guillermo
    Hammond, Danielle E.
    Swaminathan, Mahesh
    Bazinet, Alexandre
    Kimberley, Jacqueline
    Bodden, Kristy
    Schneider, Heather
    Huang, Xuelin
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S399 - S399
  • [30] A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure
    Duong, Vu H.
    Al Ali, Najla
    Zhang, Ling
    Padron, Eric
    Sallman, David
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 1901 - 1907
12345